(26) The greatest risk reduction occurred in long-term users (HR: 0.44, 95% CI: 0.270.72)
Its important to consider the risks and benefits of both long-term and short-term outcomes
Ultimately, they compared the outcomes of roughly 439,000 type 2 diabetes patients taking a GLP-1 with those of a similarly sized group of patients, closely matched in age and other characteristics, taking another medication
Diabetologia 54(11):27452754 Malavazos AE, Meregalli C, Sorrentino F, Vignati A, Dubini C, Scravaglieri V, Basilico S, Boniardi F, Spagnolo P, Malagoli P, Romanelli P, Secchi F, Iacobellis G (2023) Semaglutide therapy decreases epicardial fat inflammation and improves psoriasis severity in patients affected by abdominal obesity and type-2 diabetes
Biological pathways associated with neuroprogression in bipolar disorder
[13] [14] [15] [26] It is sold as a generic drug by several drug companies in the Indian and Canadian markets, and worldwide by its originator, Novo Nordisk, under the brand names Ozempic and Rybelsus for diabetes